Provided by Tiger Trade Technology Pte. Ltd.

Arbutus Biopharma

4.58
+0.17003.85%
Post-market: 4.57-0.0100-0.22%16:45 EDT
Volume:6.80M
Turnover:30.97M
Market Cap:901.98M
PE:5.48
High:4.63
Open:4.42
Low:4.40
Close:4.41
52wk High:5.10
52wk Low:3.04
Shares:196.94M
Float Shares:128.00M
Volume Ratio:1.74
T/O Rate:5.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.8355
EPS(LYR):-0.1748
ROE:94.73%
ROA:49.18%
PB:3.47
PE(LYR):-26.19

Loading ...

Company Profile

Company Name:
Arbutus Biopharma
Exchange:
NASDAQ
Establishment Date:
2005
Employees:
19
Office Location:
701 Veterans Circle,Warminster,Pennsylvania,United States
Zip Code:
18974
Fax:
- -
Introduction:
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-161, an oral HBV RNA destabilizer; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate AB-729. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Directors

Name
Position
Lindsay Androski
Director,Chairperson of the Board,Chief Executive Officer and President
Joseph Bishop
Independent Director
Matthew Gline
Independent Director
Robert A. Beardsley
Independent Director
Roger Sawhney
Independent Director

Shareholders

Name
Position
Lindsay Androski
Director,Chairperson of the Board,Chief Executive Officer and President
Tuan Nguyen
Chief Financial Officer